AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9164808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-mineral formula (1350 mg of calcium per liter and 900 mg of phosphorus per liter)
Number of subjects: 101
Study 9164808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk (1230 mg of calcium per liter and 960 mg of phosphorus per liter)
Number of subjects: 101
Study 8420273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon-flavored Colyte
Number of subjects: 56
Study 8420273 — intervention group
Group type: COMPARATOR
Intervention: Standard Colyte
Number of subjects: 56
Study 8420273 — intervention group
Group type: COMPARATOR
Intervention: NuLYTELY
Number of subjects: 56
Study 3090860 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg DSCG rectally as enemas for eight weeks
Number of subjects: 43
Study 3090860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 43
Study 30356126 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 427
Study 30356126 — intervention group
Group type: COMPARATOR
Intervention: Pelvic external beam radiotherapy (EBRT)
Number of subjects: 427
Study 27178980 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote care
Number of subjects: 60
Study 24753014 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic stable amorphous calcium carbonate (ACC)
Number of subjects: 15
Study 24753014 — intervention group
Group type: COMPARATOR
Intervention: Crystalline calcium carbonate (CCC)
Number of subjects: 15
Study 22629225 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 20
Study 22629225 — intervention group
Group type: COMPARATOR
Intervention: Cyriax physiotherapy
Number of subjects: 20
Study 20234364 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+ZOL (neoadjuvant chemotherapy with zoledronic acid)
Number of subjects: 205
Study 20234364 — intervention group
Group type: COMPARATOR
Intervention: CT (neoadjuvant chemotherapy)
Number of subjects: 205
Study 20234364 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+ZOL
Number of subjects: 205
Study 20234364 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 205
Study 18296121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 101
Study 18296121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 16135352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 CUN lateral to the femoral artery
Number of subjects: 62
Study 16135352 — intervention group
Group type: COMPARATOR
Intervention: 1 cm lateral to the femoral artery
Number of subjects: 62
Study 16135352 — intervention group
Group type: COMPARATOR
Intervention: 2 cm lateral to the femoral artery
Number of subjects: 62
Study 12655261 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 25
Study 12655261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg twice daily
Number of subjects: 25
Study 12655261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of 10 mg/m2
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of 30 mg/m2
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. bolus of 20 mg/m2
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. administration
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. dosing compared to i.v. dosing
Number of subjects: 12
Study 11185667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribozyme administration
Number of subjects: 12
Study 9264752 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement measures for hygiene and water supply, installation of latrines, and health education
Number of subjects: 0
Study 1492863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 6 mg tablet daily for four months
Number of subjects: 200
Study 1492863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 2871007 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, 160 mg/day)
Number of subjects: 22
Study 2871007 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN, 100 mg/day)
Number of subjects: 22
Study 28187041 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 204
Study 28187041 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 204
Study 26767340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple contests
Number of subjects: 1217
Study 26767340 — intervention group
Group type: COMPARATOR
Intervention: Single contest
Number of subjects: 1217
Study 26767340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple contests with counseling
Number of subjects: 1217
Study 26767340 — intervention group
Group type: COMPARATOR
Intervention: Single contest plus counseling
Number of subjects: 1217
Study 24611528 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 242
Study 24611528 — intervention group
Group type: COMPARATOR
Intervention: Community Practice
Number of subjects: 242
Study 22219412 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization by PCI
Number of subjects: 1766
Study 22219412 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization by PCI
Number of subjects: 1766
Study 22219412 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization by CABG
Number of subjects: 1766
Study 20528963 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 22
Study 20528963 — intervention group
Group type: COMPARATOR
Intervention: Semilunar Coronally Re-positioned Flap (SLCRF)
Number of subjects: 22
Study 18610754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 20
Study 18610754 — intervention group
Group type: COMPARATOR
Intervention: MLT alone
Number of subjects: 20
Study 18610754 — intervention group
Group type: COMPARATOR
Intervention: MLT plus 5-MTT
Number of subjects: 20
Study 16061827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs
Number of subjects: 43
Study 16061827 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 individuals)
Number of subjects: 43
Study 12911137 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subjects
Number of subjects: 30
Study 12911137 — intervention group
Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 30
Study 9696964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg three times daily for 9 days)
Number of subjects: 13
Study 9696964 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.5 mg twice a day for 1 day, then 0.25 mg once a day for 8 days)
Number of subjects: 13
Study 9696964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of tiagabine and digoxin
Number of subjects: 13
Study 7641777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic oesophageal, gastric and duodenal biopsy
Number of subjects: 31
Study 2830108 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (sodium bicarbonate)
Number of subjects: 6
Study 2830108 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 2830108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 6
Study 29361433 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text message intervention for 1 year
Number of subjects: 700
Study 29361433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 700
Study 26867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Copers (AC)
Number of subjects: 666
Study 26867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonally Distressed (ID)
Number of subjects: 666
Study 26867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional (DYS)
Number of subjects: 666
Study 24723487 — intervention group
Group type: EXPERIMENTAL
Intervention: BEV/IRI (neo-adjuvant intravenous BEV, 10 mg/kg, and IRI, 125 mg/m², every 2 weeks for four cycles before RT; adjuvant BEV and IRI every 2 weeks for 6 months)
Number of subjects: 120
Study 24723487 — intervention group
Group type: COMPARATOR
Intervention: Control (concomitant oral TMZ, 75 mg/m²/day during RT, and 150-200 mg/m² for 5 days every 28 days for 6 months)
Number of subjects: 120
Study 23245780 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Friends: Get Movin' With Mighty Moves(®) program
Number of subjects: 201
Study 23245780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 21558573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 20
Study 21558573 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 19560259 — intervention group
Group type: EXPERIMENTAL
Intervention: Open nephroureterectomy (ONU)
Number of subjects: 80
Study 19560259 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic nephroureterectomy (LNU)
Number of subjects: 80
Study 16443447 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariation information presented with natural language quantifiers in Experiment 1
Number of subjects: 0
Study 16443447 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariation information presented with natural language quantifiers in Experiments 2-4
Number of subjects: 0
Study 16443447 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution experiments using vignettes with covariation information
Number of subjects: 0
Study 15233279 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]MP4A PET
Number of subjects: 13
Study 15233279 — intervention group
Group type: COMPARATOR
Intervention: [123I]IMP SPECT
Number of subjects: 13
Study 11378811 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (150 mg), alpha-tocopherol (75 mg), beta-carotene (15 mg), selenium (101 microg), and calcium (1.6 g)
Number of subjects: 116
Study 11378811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 116
Study 9218294 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine-loaded polymer (active treatment)
Number of subjects: 32
Study 9218294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study 8356525 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal venovenous recirculation (EVR)
Number of subjects: 15
Study 8356525 — intervention group
Group type: COMPARATOR
Intervention: Control (existing therapy)
Number of subjects: 15
Study 3902354 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing washing powder (alcalase)
Number of subjects: 255
Study 3902354 — intervention group
Group type: EXPERIMENTAL
Intervention: User test involving double blind wearing of vests washed with the product
Number of subjects: 255
Study 31861114 — intervention group
Group type: COMPARATOR
Intervention: Educational program for the experimental group (EG) consisting of classes held on Saturday mornings (8:00 to 10:00 a.m.) for two months.
Number of subjects: 589
Study 31861114 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) consisting of students from public and private schools who did not receive the educational intervention.
Number of subjects: 589
Study 29688579 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat 500 mg
Number of subjects: 110
Study 29688579 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat 300 mg
Number of subjects: 110
Study 29688579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26637834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9105
Study 26637834 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9105
Study 24708300 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic pyelolithotomy (RLP)
Number of subjects: 178
Study 24708300 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 178
Study 22820910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 162
Study 22820910 — intervention group
Group type: EXPERIMENTAL
Intervention: Norclozapine
Number of subjects: 162
Study 22820910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and Norclozapine
Number of subjects: 162
Study 20470281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet plus fosinopril (group 1)
Number of subjects: 85
Study 20470281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet plus fosinopril plus spironolactone (group 2)
Number of subjects: 85
Study 18633043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block with 15 mL of ropivacaine 7.5 mg/mL
Number of subjects: 40
Study 18633043 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 17723130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rFVIIa prophylaxis with 90 microg kg(‐1) for 3 months
Number of subjects: 38
Study 17723130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rFVIIa prophylaxis with 270 microg kg(‐1) for 3 months
Number of subjects: 38
Study 17723130 — intervention group
Group type: COMPARATOR
Intervention: Conventional on‐demand therapy
Number of subjects: 38
Study 15115999 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic saphenectomy
Number of subjects: 40
Study 15115999 — intervention group
Group type: COMPARATOR
Intervention: Open saphenectomy
Number of subjects: 40
Study 11137071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization by Hulka clips
Number of subjects: 46
Study 11137071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization by Filshie clips
Number of subjects: 46
Study 11137071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization (both methods)
Number of subjects: 46
Study 9361660 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Frequency Bioelectrical Impedance Analysis (MFBIA)
Number of subjects: 53
Study 9361660 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MFBIA measurement
Number of subjects: 53
Study 9361660 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial MFBIA measurements
Number of subjects: 53
Study 1571118 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate (900 mg) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Number of subjects: 100
Study 1571118 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin sodium (2 g) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Number of subjects: 100
Study 3911880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid
Number of subjects: 104
Study 3911880 — intervention group
Group type: COMPARATOR
Intervention: Co‐trimoxazole
Number of subjects: 104
Study 29851070 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (0.02 g kg‐1 of an association of Lactobacillus acidophilus, Enterococcus faecium, Bifidobacterium thermophilum, and Bifidobacterium longum) with K2 Cr2 O7
Number of subjects: 96
Study 29851070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic, no K2 Cr2 O7)
Number of subjects: 96
Study 29851070 — intervention group
Group type: EXPERIMENTAL
Intervention: K2 Cr2 O7 at doses of 0.12 g kg‐1, 0.24 g kg‐1, and 0.36 g kg‐1
Number of subjects: 96
Study 28400245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall task for original items
Number of subjects: 75
Study 28400245 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal responses during CIT
Number of subjects: 75
Study 28400245 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic measures in CIT
Number of subjects: 75
Study 25239014 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multifactorial, interdisciplinary intervention
Number of subjects: 241
Study 25239014 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 241
Study 23540531 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical alignment method
Number of subjects: 117
Study 23540531 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical alignment method
Number of subjects: 117
Study 21531737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 71
Study 21531737 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 71
Study 19660204 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 36
Study 19660204 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 36
Study 16043377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI) score for TBI group
Number of subjects: 10
Study 16043377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Organization Test score for TBI group
Number of subjects: 10
Study 16043377 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical model kinematics for TBI group
Number of subjects: 10
Study 16043377 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between DHI and posturography
Number of subjects: 10
Study 16043377 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion of the COM and DHI score prediction
Number of subjects: 10
Study 12399846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision (harmonic scissors) in group 1 (331 patients)
Number of subjects: 461
Study 12399846 — intervention group
Group type: COMPARATOR
Intervention: Endo-loop in group 2 (130 patients)
Number of subjects: 461
Study 12206010 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms.kg‐1 (Group F1)
Number of subjects: 42
Study 12206010 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 micrograms.kg‐1 (Group F2)
Number of subjects: 42
Study 12206010 — intervention group
Group type: EXPERIMENTAL
Intervention: URA 0.25 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U1)
Number of subjects: 42
Study 12206010 — intervention group
Group type: EXPERIMENTAL
Intervention: URA 0.5 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U2)
Number of subjects: 42
Study 9108849 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant factor VIII (rFVIII)
Number of subjects: 10
Study 9108849 — intervention group
Group type: COMPARATOR
Intervention: highly purified plasma‐derived factor VIII (pdFVIII)
Number of subjects: 10
Study 1287904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 79
Study 1287904 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 79
Study 1287904 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 79
Study 3903734 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program to reduce high blood pressure, elevated blood cholesterol, and/or cigarette smoking
Number of subjects: 1000
Study 3903734 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1000
Study 3903734 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program
Number of subjects: 1000
Study 31077773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostalgic food labels
Number of subjects: 0
Study 31077773 — intervention group
Group type: COMPARATOR
Intervention: Descriptive food labels
Number of subjects: 0
Study 29630033 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB) with 20 mL of levobupivacaine 0.5% and epinephrine 5 μg/mL
Number of subjects: 0
Study 29630033 — intervention group
Group type: COMPARATOR
Intervention: Small-volume supraclavicular block (SCB) with 20 mL of levobupivacaine 0.5%
Number of subjects: 0
Study 29630033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ISB and SCB
Number of subjects: 0
Study 27064369 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using the novel negative pressure device (NPD)
Number of subjects: 0
Study 27064369 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure ulcer (PU) wound dressing
Number of subjects: 0
Study 24216257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Education Program (NEP)
Number of subjects: 120
Study 24216257 — intervention group
Group type: COMPARATOR
Intervention: Oral Supplementation (OS)
Number of subjects: 120
Study 22767646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group VC (VPA)
Number of subjects: 55
Study 22767646 — intervention group
Group type: COMPARATOR
Intervention: Group C (Control)
Number of subjects: 55
Study 22767646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group VM (VPA + MgSO4)
Number of subjects: 55
Study 22767646 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study 20613550 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Number of subjects: 44
Study 20613550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17081523 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological oxygen concentration (5% O(2), 5% CO(2), and 90% N(2))
Number of subjects: 106
Study 17081523 — intervention group
Group type: COMPARATOR
Intervention: Atmospheric oxygen concentration (5% CO(2) with the balance as air)
Number of subjects: 106
Study 16054520 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5, 5 x 10(7) cfu/tablet)
Number of subjects: 479
Study 16054520 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 479
Study 16054520 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 479
Study 11199957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release 300 mg/day
Number of subjects: 13
Study 11199957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9531003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed intake of carbohydrate-electrolyte solution (6.9% Lucozade-Sport; sodium, 24 mmol l(‐1); potassium, 2.6 mmol l(‐1); calcium, 1.2 mmol l(‐1); osmolality, 300 mOsm kg(‐1))
Number of subjects: 7